ME03489B - Molekuli antitijela na tim-3 i njihove upotrebe - Google Patents
Molekuli antitijela na tim-3 i njihove upotrebeInfo
- Publication number
- ME03489B ME03489B MEP-2019-177A MEP2019177A ME03489B ME 03489 B ME03489 B ME 03489B ME P2019177 A MEP2019177 A ME P2019177A ME 03489 B ME03489 B ME 03489B
- Authority
- ME
- Montenegro
- Prior art keywords
- team
- antibody molecules
- antibody
- molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934469P | 2014-01-31 | 2014-01-31 | |
| US201462094912P | 2014-12-19 | 2014-12-19 | |
| PCT/US2015/013913 WO2015117002A1 (en) | 2014-01-31 | 2015-01-30 | Antibody molecules to tim-3 and uses thereof |
| EP15705163.2A EP3099717B1 (en) | 2014-01-31 | 2015-01-30 | Antibody molecules to tim-3 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03489B true ME03489B (me) | 2020-01-20 |
Family
ID=52478098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-177A ME03489B (me) | 2014-01-31 | 2015-01-30 | Molekuli antitijela na tim-3 i njihove upotrebe |
Country Status (34)
| Country | Link |
|---|---|
| US (6) | US9605070B2 (me) |
| EP (3) | EP3560959B1 (me) |
| JP (3) | JP6539667B2 (me) |
| KR (2) | KR102366218B1 (me) |
| CN (2) | CN106132991B (me) |
| AU (2) | AU2015210750B2 (me) |
| CA (1) | CA2936863A1 (me) |
| CL (1) | CL2016001716A1 (me) |
| CR (1) | CR20160347A (me) |
| CU (1) | CU24427B1 (me) |
| CY (1) | CY1121893T1 (me) |
| DK (1) | DK3099717T3 (me) |
| EA (1) | EA201691556A1 (me) |
| EC (1) | ECSP16070447A (me) |
| ES (2) | ES2972425T3 (me) |
| HR (1) | HRP20191083T1 (me) |
| HU (1) | HUE045065T2 (me) |
| IL (1) | IL246693B2 (me) |
| JO (2) | JOP20200096A1 (me) |
| LT (1) | LT3099717T (me) |
| ME (1) | ME03489B (me) |
| MX (2) | MX375953B (me) |
| MY (1) | MY187296A (me) |
| NZ (2) | NZ761188A (me) |
| PE (1) | PE20170330A1 (me) |
| PH (1) | PH12016501482B1 (me) |
| PL (1) | PL3099717T3 (me) |
| PT (1) | PT3099717T (me) |
| RS (1) | RS59065B1 (me) |
| SG (1) | SG11201605627TA (me) |
| SI (1) | SI3099717T1 (me) |
| TW (2) | TWI686406B (me) |
| UY (1) | UY35973A (me) |
| WO (1) | WO2015117002A1 (me) |
Families Citing this family (349)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709412B2 (en) * | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
| EP3130350A1 (en) * | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| EP2408818A1 (en) * | 2009-03-17 | 2012-01-25 | Université de la Méditerranée | Btla antibodies and uses thereof |
| CA2828753C (en) | 2011-03-16 | 2022-07-26 | arGEN-X BV | Antibodies to cd70 |
| ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CN114081946A (zh) | 2014-03-12 | 2022-02-25 | 耶达研究与开发有限公司 | 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤 |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| CA2936962C (en) | 2014-03-14 | 2024-03-05 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| US10301273B2 (en) | 2014-08-07 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3662903A3 (en) * | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CN114107424A (zh) | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| CA2964367C (en) | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| GB201419094D0 (en) * | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| US10259874B2 (en) | 2014-10-27 | 2019-04-16 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| DK4141032T3 (da) | 2014-11-20 | 2024-08-05 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister |
| DK3221356T3 (da) | 2014-11-20 | 2020-11-02 | Hoffmann La Roche | T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3 |
| DK3221357T3 (da) | 2014-11-20 | 2020-08-10 | Hoffmann La Roche | Fælles letkæder og fremgangsmåder til anvendelse |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| HK1247089A1 (zh) | 2015-03-10 | 2018-09-21 | Aduro Biotech, Inc. | 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
| EP3628688A1 (en) | 2015-03-23 | 2020-04-01 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
| DK3277321T3 (da) | 2015-04-01 | 2024-09-02 | Anaptysbio Inc | Antistoffer, der er rettet mod T-celle-immunglobulin og mucin-protein 3 (TIM-3) |
| WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US20180153986A1 (en) * | 2015-04-24 | 2018-06-07 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| RU2752729C2 (ru) | 2015-05-18 | 2021-07-30 | Сумитомо Даиниппон Фарма Онколоджи, Инк. | Пролекарства альвоцидиба, имеющие повышенную биодоступность |
| MA47395A (fr) * | 2015-05-27 | 2019-12-11 | Ucb Biopharma Sprl | Méthode pour le traitement d'une maladie neurologique |
| AR105433A1 (es) | 2015-07-21 | 2017-10-04 | Novartis Ag | Métodos para mejorar la eficacia y expansión de las células inmunes |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| US20180207273A1 (en) * | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| JO3620B1 (ar) * | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| WO2017031242A1 (en) | 2015-08-20 | 2017-02-23 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
| KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| US10947598B2 (en) | 2015-09-29 | 2021-03-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for determining the metabolic status of lymphomas |
| RS62258B1 (sr) | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Bispecifična antitela specifična za pd1 i tim3 |
| BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
| CN108367070B (zh) | 2015-11-04 | 2022-10-28 | 杜克大学 | 免疫毒素与检查点抑制剂的组合治疗 |
| WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| EP3393504B1 (en) | 2015-12-22 | 2025-09-24 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| ES2837155T3 (es) | 2016-01-04 | 2021-06-29 | Inst Nat Sante Rech Med | Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales |
| MX2018008592A (es) | 2016-01-11 | 2018-12-10 | Novartis Ag | Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos. |
| TWI805127B (zh) | 2016-03-04 | 2023-06-11 | 美商Ｊｎ生物科學有限責任公司 | 針對tigit之抗體 |
| WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| HRP20211820T1 (hr) | 2016-04-12 | 2022-03-04 | Symphogen A/S | Anti-tim-3 protutijela i pripravci |
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| KR20230091191A (ko) * | 2016-05-27 | 2023-06-22 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| US12145993B2 (en) * | 2016-06-08 | 2024-11-19 | Shanghai Jiao Tong University School Of Medicine | Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity |
| US11369618B2 (en) | 2016-06-17 | 2022-06-28 | The Trustees Of The University Of Pennsylvania | Compounds, compositions and methods for prevention and/or treatment of cancer |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| SG10201911972QA (en) | 2016-07-14 | 2020-02-27 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
| AU2017297603A1 (en) | 2016-07-14 | 2019-02-14 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| EP4650005A2 (en) * | 2016-07-15 | 2025-11-19 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| EP3490548A4 (en) * | 2016-08-01 | 2020-04-15 | Molecular Templates, Inc. | ADMINISTRATION OF HYPOXIA-ACTIVATED DRUGS IN COMBINATION WITH IMMUNOMODULATORS FOR THE TREATMENT OF CANCER |
| JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| EP3970749A1 (en) * | 2016-08-26 | 2022-03-23 | BeiGene, Ltd. | Anti-tim-3 antibodies and use thereof |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| TWI764943B (zh) * | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
| MA46113A (fr) * | 2016-11-01 | 2019-07-10 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3) |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CN108101989A (zh) * | 2016-11-24 | 2018-06-01 | 复旦大学 | 针对人tim-3的全人源单域抗体及应用 |
| US11230596B2 (en) | 2016-11-30 | 2022-01-25 | Mereo Biopharma 5, Inc. | Methods for treatment of cancer comprising TIGIT-binding agents |
| AU2017368332A1 (en) | 2016-12-03 | 2019-06-13 | Juno Therapeutics, Inc. | Methods for modulation of CAR-T cells |
| CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
| JP6839761B2 (ja) | 2016-12-08 | 2021-03-10 | イーライ リリー アンド カンパニー | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 |
| JOP20190133A1 (ar) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| TWI665216B (zh) * | 2016-12-29 | 2019-07-11 | 財團法人生物技術開發中心 | 抗人類tim-3抗體及其使用方法 |
| CN108264557B (zh) * | 2016-12-30 | 2021-08-24 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用 |
| EP3565598A4 (en) * | 2017-01-03 | 2020-10-28 | Trellis Bioscience, LLC | NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS |
| TWI841209B (zh) * | 2017-01-09 | 2024-05-01 | 美商提薩羅有限公司 | 用抗tim-3抗體治療癌症之方法 |
| US11525006B2 (en) | 2017-01-23 | 2022-12-13 | Crage Medical Co., Limited | BCMA-targeting antibody and use thereof |
| AU2018219864B2 (en) | 2017-02-10 | 2025-02-27 | Mayo Foundation For Medical Education And Research | Trailshort antibody and methods of use |
| EP3585813A1 (en) * | 2017-02-22 | 2020-01-01 | Sutro Biopharma, Inc. | Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| WO2018153366A1 (zh) | 2017-02-27 | 2018-08-30 | 江苏恒瑞医药股份有限公司 | Tim-3抗体、其抗原结合片段及医药用途 |
| US11596629B2 (en) * | 2017-02-28 | 2023-03-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
| JOP20190218A1 (ar) | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
| US20210186982A1 (en) | 2017-03-24 | 2021-06-24 | Universite Nice Sophia Antipolis | Methods and compositions for treating melanoma |
| PT3600282T (pt) | 2017-03-31 | 2025-11-05 | Corcept Therapeutics Inc | Moduladores de recetores de glucocorticoides para tratar cancro cervical |
| AU2018247916B2 (en) | 2017-04-05 | 2025-04-24 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
| JOP20190222A1 (ar) * | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| CN108948193B (zh) * | 2017-05-18 | 2022-12-09 | 上海健信生物医药科技有限公司 | 针对tim-3的抗体分子,抗原结合片段及其医药用途 |
| CN111107868A (zh) | 2017-05-24 | 2020-05-05 | 诺华股份有限公司 | 抗体细胞因子移植蛋白及使用方法 |
| WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
| PE20251254A1 (es) | 2017-05-24 | 2025-05-06 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer |
| JP7187486B2 (ja) | 2017-05-25 | 2022-12-12 | レイドス， インコーポレイテッド | Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド |
| WO2018223004A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| AU2018275109A1 (en) | 2017-06-01 | 2020-01-02 | Xencor, Inc. | Bispecific antibodies that bind CD 123 CD3 |
| WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| TW201904993A (zh) | 2017-06-22 | 2019-02-01 | 瑞士商諾華公司 | IL-1β 結合抗體之用途 |
| MX2019015738A (es) | 2017-06-27 | 2020-02-20 | Novartis Ag | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. |
| CA3067602A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| AU2018302283B2 (en) | 2017-07-20 | 2025-07-10 | Novartis Ag | Dosage regimens of anti-LAG-3 antibodies and uses thereof |
| FI3658141T3 (fi) * | 2017-07-24 | 2023-03-02 | Patologisten tilojen hoitaminen suoralla tai epäsuoralla siralfa-cd47-vuorovaikutukseen kohdentamisella | |
| WO2019023247A1 (en) * | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| EA202090401A1 (ru) * | 2017-07-28 | 2020-05-18 | Фейнз Терапьютикс, Инк. | Анти-tim-3 антитела и их применение |
| EP3676616A1 (en) * | 2017-08-28 | 2020-07-08 | Bristol-Myers Squibb Company | Tim-3 antagonists for the treatment and diagnosis of cancers |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| CN109554469B (zh) * | 2017-09-26 | 2021-10-12 | 北京大学 | T细胞急性淋巴性白血病的肿瘤细胞及其分子标志 |
| US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| WO2019094268A1 (en) | 2017-11-10 | 2019-05-16 | Armo Biosciences, Inc. | Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors |
| CA3081602A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| JP6846574B2 (ja) | 2017-11-29 | 2021-03-24 | 大鵬薬品工業株式会社 | スルホンアミド化合物およびその使用 |
| AU2018375738A1 (en) | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
| CN109870581B (zh) * | 2017-12-04 | 2021-05-04 | 厦门万泰凯瑞生物技术有限公司 | 一种定量检测HBsAg的试剂盒及方法 |
| WO2019117659A1 (ko) * | 2017-12-14 | 2019-06-20 | 엘지전자 주식회사 | 움직임 벡터 도출을 기반으로 하는 영상 코딩 방법 및 그 장치 |
| WO2019118855A1 (en) * | 2017-12-14 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Compounds and compositions for prevention and/or treatment of cancer |
| CN112204048A (zh) | 2017-12-15 | 2021-01-08 | 朱诺治疗学股份有限公司 | 抗cct5结合分子及其使用方法 |
| WO2019134946A1 (en) | 2018-01-04 | 2019-07-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma resistant |
| CR20200334A (es) | 2018-01-05 | 2021-03-09 | Cybrexa 1 Inc | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| CN111886255B (zh) | 2018-01-12 | 2025-04-04 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| WO2019143607A1 (en) | 2018-01-16 | 2019-07-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN111971059A (zh) | 2018-01-31 | 2020-11-20 | 细胞基因公司 | 使用过继细胞疗法和检查点抑制剂的组合疗法 |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| WO2019162325A1 (en) | 2018-02-21 | 2019-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors |
| AU2018410849B2 (en) | 2018-02-27 | 2025-02-27 | Leidos, Inc. | PD-1 peptide inhibitors |
| CN110272489B (zh) * | 2018-03-15 | 2023-08-22 | 上海健信生物医药科技有限公司 | 一种针对tim-3的全人源化抗体分子, 抗原结合片段及其医药用途 |
| CN110305216B (zh) * | 2018-03-20 | 2022-09-02 | 无锡智康弘义生物科技有限公司 | 新型抗tim-3抗体 |
| WO2019179420A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-tim-3 antibodies |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| JP2021519279A (ja) | 2018-03-27 | 2021-08-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾環式ジヌクレオチド化合物 |
| US20210009627A1 (en) | 2018-03-27 | 2021-01-14 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]trizain-7-one as string agonists |
| WO2019196911A1 (en) * | 2018-04-12 | 2019-10-17 | Nanjing Leads Biolabs Co., Ltd. | Antibody binding tim-3 and use thereor |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| MX2020010910A (es) | 2018-04-18 | 2021-02-09 | Xencor Inc | Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos. |
| SG11202010159RA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| EP3785732A4 (en) * | 2018-04-24 | 2022-02-23 | Ampsource Biopharma Shanghai Inc. | Antibody against tim-3 and application thereof |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EA202092460A1 (ru) | 2018-05-23 | 2021-03-24 | Бейджин, Лтд. | Антитела к ox40 и способы применения |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019232528A1 (en) | 2018-06-01 | 2019-12-05 | Xencor, Inc. | Dosing of a bispecific antibody that bind cd123 and cd3 |
| CN118459594A (zh) | 2018-06-01 | 2024-08-09 | 诺华股份有限公司 | 针对bcma的结合分子及其用途 |
| KR102589213B1 (ko) | 2018-06-04 | 2023-10-12 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| JP7097465B2 (ja) | 2018-06-19 | 2022-07-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法 |
| US20210269521A1 (en) * | 2018-07-03 | 2021-09-02 | L&L Biopharma Co., Ltd. | Bispecific antibody and use thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| DK3820573T3 (da) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| TWI822815B (zh) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | 抗-人類ｐｄ-ｌ１之抗體及其用途 |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| JP7555327B2 (ja) | 2018-07-25 | 2024-09-24 | ノバルティス アーゲー | Ｎｌｒｐ３インフラマソーム阻害剤 |
| US20220017618A1 (en) * | 2018-08-20 | 2022-01-20 | Jiangsu Hengrui Medicine Co., Ltd. | Use of tim-3 antibody in preparation of medicines for treating tumors |
| SG11202012148RA (en) * | 2018-08-21 | 2021-01-28 | Albert Einstein College Medicine | Monoclonal antibodies against human tim-3 |
| KR20210053294A (ko) | 2018-08-28 | 2021-05-11 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-tim3 항체 제약 조성물 및 이의 용도 |
| CN113365663B (zh) | 2018-08-30 | 2025-11-21 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| KR20250160211A (ko) | 2018-08-30 | 2025-11-11 | 이뮤니티바이오, 인크. | 다중-사슬 키메라 폴리펩타이드 및 이의 용도 |
| JP7474769B2 (ja) * | 2018-08-30 | 2024-04-25 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 一本鎖および多鎖キメラポリペプチドならびにその使用方法 |
| MY206167A (en) | 2018-09-26 | 2024-12-03 | Astellas Pharma Inc | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
| EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
| EP3856782A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| WO2020070062A1 (en) | 2018-10-01 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma |
| CA3115096A1 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| MA53862A (fr) | 2018-10-12 | 2022-01-19 | Xencor Inc | Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci |
| WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
| CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| EP3873611A1 (en) | 2018-11-01 | 2021-09-08 | Merck Patent GmbH | Anti-tim-3 antibodies |
| PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
| CA3117371A1 (en) * | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Methods of administering anti-tim-3 antibodies |
| WO2020102721A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als) |
| KR20210104713A (ko) | 2018-11-16 | 2021-08-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법 |
| EP3883964A1 (en) | 2018-11-20 | 2021-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Bispecific antibody targeting transferrin receptor 1 and soluble antigen |
| WO2020104479A1 (en) | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
| WO2020113194A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
| CN113490499A (zh) | 2018-12-04 | 2021-10-08 | 大日本住友制药肿瘤公司 | 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物 |
| WO2020115261A1 (en) | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| WO2020120592A1 (en) | 2018-12-12 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating melanoma |
| TWI848030B (zh) | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| WO2020127411A1 (en) | 2018-12-19 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d |
| EP3897844B1 (en) * | 2018-12-19 | 2023-11-15 | Deutsches Krebsforschungszentrum | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| JP2022514280A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | Ｍｄｍ２阻害剤のための延長低用量レジメン |
| US20200369762A1 (en) * | 2018-12-21 | 2020-11-26 | Novartis Ag | Use of il-1beta binding antibodies |
| US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| PE20211296A1 (es) | 2018-12-21 | 2021-07-20 | Novartis Ag | Anticuerpos anti-pmel17 y conjugados de los mismos |
| KR20210108422A (ko) | 2018-12-21 | 2021-09-02 | 노파르티스 아게 | IL-1β 결합 항체의 용도 |
| WO2020127885A1 (en) | 2018-12-21 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for treating cancers and resistant cancers |
| WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND USES THEREOF |
| CN113366316B (zh) | 2019-01-30 | 2025-05-23 | 国家医疗保健研究所 | 用于鉴定患有癌症的受试者是否将获得对免疫检查点抑制剂的应答的方法和组合物 |
| CN113728233B (zh) * | 2019-01-31 | 2024-09-13 | 积水医疗株式会社 | 用于生物样品中的游离aim的免疫分析方法和分析试剂盒 |
| US20220117911A1 (en) | 2019-02-04 | 2022-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating blood-brain barrier |
| CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| WO2020165370A1 (en) | 2019-02-13 | 2020-08-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for selecting a cancer treatment in a subject suffering from cancer |
| AU2020222345B2 (en) | 2019-02-15 | 2022-11-17 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US12479817B2 (en) | 2019-02-15 | 2025-11-25 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| JP7547360B2 (ja) | 2019-03-22 | 2024-09-09 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法 |
| EP3946450A1 (en) * | 2019-04-03 | 2022-02-09 | TargImmune Therapeutics AG | Immunotherapy for the treatment of cancer |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| WO2020219963A1 (en) * | 2019-04-26 | 2020-10-29 | University Of Houston System | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
| US20220220565A1 (en) | 2019-04-30 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US11407829B2 (en) | 2019-05-22 | 2022-08-09 | Leidos, Inc. | LAG3 binding peptides |
| AU2020283299B2 (en) * | 2019-05-29 | 2024-08-01 | Taiho Pharmaceutical Co., Ltd. | Combination treatment of cancer using sulfonamide compound and immune regulator |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CN114650842A (zh) * | 2019-06-21 | 2022-06-21 | 单细胞技术股份有限公司 | 抗tim-3抗体 |
| EP3994132A1 (en) | 2019-07-03 | 2022-05-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
| WO2021007160A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| PH12022550039A1 (en) | 2019-07-10 | 2023-06-26 | Cybrexa 3 Inc | Peptide conjugates of cytotoxins as therapeutics |
| MX2022000450A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos. |
| CN110407938B (zh) * | 2019-08-12 | 2020-03-06 | 北京昭衍生物技术有限公司 | 抗tim-3单克隆抗体、表达载体及其应用 |
| JP2022547234A (ja) | 2019-08-29 | 2022-11-10 | アステラス製薬株式会社 | 遺伝子操作された腫瘍溶解性ワクシニアウイルスおよびその使用方法 |
| WO2021048292A1 (en) | 2019-09-11 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| TW202124443A (zh) * | 2019-09-16 | 2021-07-01 | 瑞士商諾華公司 | 高親和力的、配位基阻斷性、人源化的抗T細胞免疫球蛋白結構域和黏蛋白結構域3(TIM-3)IgG4抗體用於治療骨髓纖維化之用途 |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| CN115916233A (zh) | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
| EP4037714A1 (en) | 2019-10-03 | 2022-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating macrophages polarization |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| US12383581B2 (en) | 2019-10-11 | 2025-08-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia |
| US12440487B2 (en) | 2019-10-16 | 2025-10-14 | Corcept Therapeutics Incorporated | Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist |
| CA3157889A1 (en) | 2019-10-17 | 2021-04-22 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for diagnosing nasal intestinal type adenocarcinomas |
| CN114786680A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | Tim-3抑制剂及其用途 |
| KR20220103947A (ko) | 2019-10-21 | 2022-07-25 | 노파르티스 아게 | 베네토클락스 및 tim-3 억제제를 사용한 조합 요법 |
| EP4051286A1 (en) | 2019-10-29 | 2022-09-07 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and compositions for treating uveal melanoma |
| KR20220103105A (ko) * | 2019-11-21 | 2022-07-21 | 베이진 엘티디 | 항-tim3 항체와 병용하여 항-ox40 항체를 사용한 암 치료 방법 |
| AU2020408198A1 (en) | 2019-12-19 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and vaccine compositions to treat cancers |
| JP2023506958A (ja) * | 2019-12-20 | 2023-02-20 | ノバルティス アーゲー | 骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ |
| US11396647B2 (en) | 2020-01-07 | 2022-07-26 | Board Of Regents, The University Of Texas System | Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| WO2021144426A1 (en) | 2020-01-17 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| IL293752A (en) | 2020-01-17 | 2022-08-01 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| EP4100126A1 (en) | 2020-02-05 | 2022-12-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki) |
| WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| KR102572804B1 (ko) * | 2020-02-25 | 2023-08-31 | 국립암센터 | CD11b+ 세포에서 TIM-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법 |
| TW202146452A (zh) | 2020-02-28 | 2021-12-16 | 瑞士商諾華公司 | 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥 |
| EP4110955A1 (en) | 2020-02-28 | 2023-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, prognosing and managing treatment of breast cancer |
| WO2021207689A2 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
| WO2021209356A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| JP7734693B2 (ja) | 2020-04-29 | 2025-09-05 | イミュニティーバイオ インコーポレイテッド | 抗ｃｄ２６タンパク質及びそれらの使用法 |
| WO2021252099A2 (en) * | 2020-05-04 | 2021-12-16 | Virginia Commonwealth University | Antimicrobial and antitoxin compositions and methods for treatment |
| WO2021231908A2 (en) * | 2020-05-15 | 2021-11-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhancing cancer immunotherapy |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CA3184756A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| AU2021284273A1 (en) | 2020-06-02 | 2022-12-15 | Arcus Biosciences, Inc. | Antibodies to TIGIT |
| US11338040B2 (en) | 2020-06-04 | 2022-05-24 | Leidos, Inc. | Immunomodulatory compounds |
| US12240899B2 (en) | 2020-06-22 | 2025-03-04 | Ngm Biopharmaceuticals, Inc. | LAIR-1-binding agents and methods of use thereof |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| US20230266332A1 (en) | 2020-07-28 | 2023-08-24 | Inserm (Institut National De La Santè Et De La Recherch Médicale) | Methods and compositions for preventing and treating a cancer |
| EP4188947A2 (en) | 2020-07-31 | 2023-06-07 | Leidos, Inc. | Lag3 binding peptides |
| WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP2023537066A (ja) | 2020-08-07 | 2023-08-30 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| CN116368154A (zh) | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| EP4225444A1 (en) | 2020-10-12 | 2023-08-16 | Leidos, Inc. | Immunomodulatory peptides |
| WO2022084531A1 (en) | 2020-10-23 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating glioma |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| WO2022101484A1 (en) | 2020-11-16 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
| US20230416830A1 (en) | 2020-11-16 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
| WO2022106579A1 (en) * | 2020-11-20 | 2022-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compounds for treating a disease associated with macrophage senescence |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| JP2024504923A (ja) | 2021-01-11 | 2024-02-02 | シンセカイン インコーポレイテッド | 受容体ペア形成に関する組成物および方法 |
| EP4284950A4 (en) | 2021-01-29 | 2024-12-25 | Board of Regents, The University of Texas System | METHODS OF TREATMENT OF CANCER USING KINASE INHIBITORS |
| WO2022194908A1 (en) | 2021-03-17 | 2022-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| US20240279225A1 (en) | 2021-04-08 | 2024-08-22 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| BR112023021111A2 (pt) | 2021-04-13 | 2023-12-19 | Nuvalent Inc | Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2 |
| US20240252668A1 (en) | 2021-04-16 | 2024-08-01 | Anne-Sophie BLUEMMEL | Antibody drug conjugates and methods for making thereof |
| EP4326903A1 (en) | 2021-04-23 | 2024-02-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating cell senescence accumulation related disease |
| JP2024516616A (ja) * | 2021-04-23 | 2024-04-16 | スゾウ ネオロジクス バイオサイエンス シーオー．， エルティーディー． | Ｔｉｍ－３を標的とする抗体及びその使用 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023288283A2 (en) | 2021-07-14 | 2023-01-19 | Synthekine, Inc. | Methods and compositions for use in cell therapy of neoplastic disease |
| US20240391997A1 (en) * | 2021-07-16 | 2024-11-28 | Brightpath Biotherapeutics Co., Ltd. | Anti-tim-3 antigen antibody or antibody derivative, and use thereof |
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| WO2023031366A1 (en) | 2021-09-02 | 2023-03-09 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anti-cecam6 antibodies with reduced side-effects |
| EP4427044A1 (en) | 2021-11-03 | 2024-09-11 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and compositions for treating triple negative breast cancer (tnbc) |
| US20250041261A1 (en) | 2021-12-21 | 2025-02-06 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating melanoma |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| JP2023140319A (ja) | 2022-03-22 | 2023-10-04 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| JP2025518785A (ja) | 2022-06-02 | 2025-06-19 | ブリストル－マイヤーズ スクイブ カンパニー | 抗体組成物及びその使用方法 |
| KR20250029137A (ko) | 2022-06-22 | 2025-03-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| WO2024033400A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sk2 inhibitor for the treatment of pancreatic cancer |
| EP4568670A1 (en) | 2022-08-10 | 2025-06-18 | Institut National de la Santé et de la Recherche Médicale | Sigmar1 ligand for the treatment of pancreatic cancer |
| EP4587040A1 (en) | 2022-09-14 | 2025-07-23 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy |
| EP4605000A1 (en) | 2022-10-21 | 2025-08-27 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of osteoarthritis |
| AR131320A1 (es) | 2022-12-13 | 2025-03-05 | Juno Therapeutics Inc | Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos |
| WO2024163477A1 (en) | 2023-01-31 | 2024-08-08 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| WO2024161015A1 (en) | 2023-02-03 | 2024-08-08 | Institut National de la Santé et de la Recherche Médicale | Method to treat age-related diseases |
| WO2024200571A1 (en) | 2023-03-28 | 2024-10-03 | Institut National de la Santé et de la Recherche Médicale | Method for discriminating mono-immunotherapy from combined immunotherapy in cancers |
| WO2024231384A1 (en) | 2023-05-10 | 2024-11-14 | Institut National de la Santé et de la Recherche Médicale | Compositions for treating senescence related disease |
| AU2024273407A1 (en) | 2023-05-17 | 2025-12-04 | Centre National De La Recherche Scientifique | Anti-cathepsin-d antibodies |
| WO2024245951A1 (en) | 2023-05-26 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma |
| CN116444673B (zh) * | 2023-06-14 | 2023-09-15 | 北京汇智和源生物技术有限公司 | 人源膜cd14单克隆抗体及其制备方法和应用 |
| WO2024256635A1 (en) | 2023-06-15 | 2024-12-19 | Institut National de la Santé et de la Recherche Médicale | Dpm1 inhibitor for treating cancer |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025068180A1 (en) | 2023-09-25 | 2025-04-03 | Institut National de la Santé et de la Recherche Médicale | Methods of treatment of cancer by targetting cancer - associated fibroblasts |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| WO2025078632A1 (en) | 2023-10-12 | 2025-04-17 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from cancer |
| CN117257977A (zh) * | 2023-11-07 | 2023-12-22 | 正大天晴药业集团南京顺欣制药有限公司 | 用于制备抗体药物偶联物的方法 |
| WO2025111989A1 (zh) * | 2023-11-30 | 2025-06-05 | 华东师范大学 | 嵌合抗原受体及其应用 |
| WO2025132479A1 (en) | 2023-12-18 | 2025-06-26 | Institut National de la Santé et de la Recherche Médicale | Flt3 inhibitor for modulating macrophages polarization |
| WO2025132770A1 (en) | 2023-12-22 | 2025-06-26 | Institut National de la Santé et de la Recherche Médicale | Affitins for the treatment of cancer |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025166550A1 (zh) * | 2024-02-06 | 2025-08-14 | 香港北恒生物科技有限公司 | 工程化细胞及其用途 |
| WO2025210123A1 (en) | 2024-04-03 | 2025-10-09 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for treating cancers |
| WO2025219330A1 (en) | 2024-04-15 | 2025-10-23 | Institut National de la Santé et de la Recherche Médicale | Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction |
| WO2025228998A1 (en) | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
| WO2025247829A1 (en) | 2024-05-27 | 2025-12-04 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for treating prostate cancer |
Family Cites Families (458)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4433059A (en) | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| GB2116183B (en) | 1982-03-03 | 1985-06-05 | Genentech Inc | Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| AU1807188A (en) | 1987-04-10 | 1988-11-04 | Xoma Corporation | Human monoclonal antibodies binding determinants of gram negative bacteria |
| JPH021556A (ja) | 1988-06-09 | 1990-01-05 | Snow Brand Milk Prod Co Ltd | ハイブリッド抗体及びその作製方法 |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| AU6290090A (en) | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5273743A (en) | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| EP1471142B1 (en) | 1991-04-10 | 2008-11-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| ES2123001T5 (es) | 1991-06-27 | 2009-04-16 | Bristol-Myers Squibb Company | Receptor ctl4a, proteinas de fusion que lo contienen y sus usos. |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| DK0654085T3 (da) | 1992-01-23 | 1997-09-22 | Merck Patent Gmbh | Monomere og dimere antistof-fragment-fusionsproteiner |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| DE69318016D1 (de) | 1992-05-08 | 1998-05-20 | Creative Biomolecules Inc | Mehrwertige Chimäre Proteine Anologe und Verfahren zu deren Anwendungen |
| US5260074A (en) | 1992-06-22 | 1993-11-09 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| EP1550729B1 (en) | 1992-09-25 | 2009-05-27 | Avipep Pty Limited | Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| GB9323648D0 (en) | 1992-11-23 | 1994-01-05 | Zeneca Ltd | Proteins |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| IL108501A (en) | 1994-01-31 | 1998-10-30 | Mor Research Applic Ltd | Antibodies and pharmaceutical compositions containing them |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| WO1996013583A2 (en) | 1994-10-20 | 1996-05-09 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| AU718138B2 (en) | 1995-08-29 | 2000-04-06 | Kyowa Hakko Kirin Co., Ltd. | Chimeric animal and method for constructing the same |
| US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| JP2000508892A (ja) | 1996-04-04 | 2000-07-18 | ユニリーバー・ナームローゼ・ベンノートシャープ | 多価および多特異的抗原結合タンパク |
| TW533205B (en) | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| DE69738749D1 (de) | 1996-08-16 | 2008-07-17 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2361267T3 (es) | 1997-04-07 | 2011-06-15 | Genentech Inc. | Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria. |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| CA2288994C (en) | 1997-04-30 | 2011-07-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| DE69827507T2 (de) | 1997-06-11 | 2006-03-09 | Borean Pharma A/S | Trimerisierendes modul |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| JP2001520039A (ja) | 1997-10-21 | 2001-10-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２ |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| ES2234241T3 (es) | 1998-01-23 | 2005-06-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Derivados de anticuerpo de multiples fines. |
| WO1999040196A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| CZ121599A3 (cs) | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
| JP4843138B2 (ja) | 1998-04-15 | 2011-12-21 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | Ｔ細胞阻害性受容体組成物およびその使用 |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| DK1100830T3 (da) | 1998-07-28 | 2004-01-19 | Micromet Ag | Heterominiantistoffer |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| AU774962B2 (en) | 1998-12-03 | 2004-07-15 | Regents Of The University Of California, The | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
| US7041474B2 (en) | 1998-12-30 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Nucleic acid encoding human tango 509 |
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| FR2794025A1 (fr) | 1999-05-25 | 2000-12-01 | Transgene Sa | Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere |
| WO2000073498A1 (en) | 1999-06-02 | 2000-12-07 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| ES2295040T3 (es) | 1999-07-12 | 2008-04-16 | Genentech, Inc. | Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor. |
| AU784062B2 (en) | 1999-08-23 | 2006-01-19 | Dana-Farber Cancer Institute, Inc. | Novel B7-4 molecules and uses therefor |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| PT1234031T (pt) | 1999-11-30 | 2017-06-26 | Mayo Foundation | B7-h1, uma nova molécula imunoregulatória |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| EP1299419A2 (en) | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| MXPA02012106A (es) | 2000-06-06 | 2003-06-06 | Bristol Myers Squibb Co | Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion. |
| US20020164600A1 (en) | 2000-06-28 | 2002-11-07 | Gordon Freeman | PD-L2 molecules: novel PD-1 ligands and uses therefor |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| CA2417185A1 (en) | 2000-07-25 | 2002-01-31 | Shui-On Leung | Multivalent target binding protein |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1328624B1 (en) | 2000-09-20 | 2011-11-09 | Amgen Inc. | B7-like molecules and uses thereof |
| CA2426366A1 (en) | 2000-10-20 | 2002-04-25 | Tsuneya Ohno | Fusion cells and cytokine compositions for treatment of disease |
| EP2351838A1 (en) | 2000-10-20 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Crosslinking agonistic antibodies |
| US7132109B1 (en) | 2000-10-20 | 2006-11-07 | University Of Connecticut Health Center | Using heat shock proteins to increase immune response |
| US7414171B2 (en) | 2000-11-15 | 2008-08-19 | Ono Pharmaceutical Co., Ltd. | PD-1-lacking mouse and use thereof |
| JP2002194491A (ja) | 2000-12-27 | 2002-07-10 | Daido Steel Co Ltd | ばね用鋼材 |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2002072635A2 (en) | 2001-03-13 | 2002-09-19 | University College London | Specific binding members |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| BR0208637A (pt) | 2001-04-02 | 2004-12-07 | Wyeth Corp | Pd-1, um receptor para b7-4, e usos dos mesmos |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| US6727072B2 (en) | 2001-05-01 | 2004-04-27 | Dako Corporation | EGF-r detection kit |
| US6592849B2 (en) | 2001-06-21 | 2003-07-15 | Colgate Palmolive Company | Chewing gum to control malodorous breath |
| EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| US7838220B2 (en) | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
| US8709412B2 (en) | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
| MXPA04000034A (es) | 2001-06-29 | 2005-11-23 | Univ Leland Stanford Junior | Genes regulatorios de celulas t metodos para utilizar los mismos. |
| JP2003029846A (ja) | 2001-07-11 | 2003-01-31 | Sanyo Electric Co Ltd | 流量調整器および流量調整器を備えた飲料供給装置 |
| JP4249013B2 (ja) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Ｐｄ−１に対し特異性を有する物質 |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
| IL145926A0 (en) | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
| DK1441737T3 (da) | 2001-10-30 | 2006-11-13 | Novartis Ag | Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| AU2002357072A1 (en) | 2001-12-07 | 2003-06-23 | Centocor, Inc. | Pseudo-antibody constructs |
| JP4694128B2 (ja) | 2002-01-30 | 2011-06-08 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法 |
| CN101717410B (zh) | 2002-02-01 | 2015-04-29 | 阿里亚德医药股份有限公司 | 含磷化合物及其应用 |
| EP1487879B1 (en) | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| MXPA04008893A (es) | 2002-03-13 | 2005-06-20 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilados como inhibidores de mek. |
| AU2003227504A1 (en) | 2002-04-15 | 2003-10-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF CONSTRUCTING scDb LIBRARY |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US7052694B2 (en) | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
| US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
| PT1572106E (pt) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Métodos para prevenção e tratamento de metástase de cancro e perda óssea associada a metástase de cancro |
| US7449300B2 (en) | 2002-11-21 | 2008-11-11 | Mayo Foundation For Medical Education And Research | Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| DK1611112T3 (da) | 2003-02-11 | 2012-11-19 | Cancer Res Inst | Isoxazolforbindelser som hæmmere af varmechokproteiner |
| CA2517287C (en) | 2003-02-28 | 2022-12-13 | The Johns Hopkins University | Regulation of t cells by lag-3 (cd223) |
| GB0305702D0 (en) | 2003-03-12 | 2003-04-16 | Univ Birmingham | Bispecific antibodies |
| CA2522819A1 (en) | 2003-04-22 | 2004-11-04 | Immunomedics, Inc. | Polyvalent protein complex |
| US7618632B2 (en) | 2003-05-23 | 2009-11-17 | Wyeth | Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| AU2004252171B2 (en) | 2003-06-27 | 2011-04-21 | Biogen Ma Inc. | Modified binding molecules comprising connecting peptides |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| KR20060089732A (ko) | 2003-10-03 | 2006-08-09 | 브라이엄 앤드 위민즈 하스피틀 | Ｔｉｍ-3 리간드 및 그의 방법 |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| EP1682103A1 (en) | 2003-10-27 | 2006-07-26 | Novartis AG | Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation |
| WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
| EP1697748A4 (en) | 2003-12-22 | 2007-07-04 | Centocor Inc | METHODS FOR GENERATING MULTIMEDIA MOLECULES |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| EP1711495A2 (en) | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
| US8383575B2 (en) | 2004-01-30 | 2013-02-26 | Paul Scherrer Institut | (DI)barnase-barstar complexes |
| AU2005231685A1 (en) | 2004-03-24 | 2005-10-20 | Telos Pharmaceuticals Llc | Compositions as adjuvants to improve immune responses to vaccines and methods of use |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| HRP20161751T1 (hr) | 2004-05-13 | 2017-04-07 | Icos Corporation | Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta |
| EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| PL1761528T3 (pl) | 2004-06-11 | 2008-05-30 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| EP1768999B1 (en) | 2004-06-30 | 2013-06-19 | Mayo Foundation For Medical Education And Research | sHIgM12 antibody useful to treat multiple sclerosis |
| WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
| WO2006021955A2 (en) | 2004-08-23 | 2006-03-02 | Mor Research Applications Ltd. | Use of bat monoclonal antibody for immunotherapy |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| HUE039237T2 (hu) | 2004-10-06 | 2018-12-28 | Mayo Found Medical Education & Res | B7-H1 és PD-1 vesesejt karcinoma kezelésében |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| CA2602777C (en) | 2005-03-25 | 2018-12-11 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| CN101484182B (zh) | 2005-04-06 | 2014-06-11 | Ibc药品公司 | 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途 |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| ES2547463T3 (es) | 2005-06-17 | 2015-10-06 | Merck Sharp & Dohme Corp. | Moléculas de unión a ILT3 y usos de las mismas |
| WO2007004415A1 (ja) | 2005-07-01 | 2007-01-11 | Murata Manufacturing Co., Ltd. | 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PL1912671T3 (pl) | 2005-07-18 | 2018-02-28 | Seattle Genetics, Inc. | Koniugaty beta-glukuronid-linker-lek |
| AU2006283532B2 (en) | 2005-08-19 | 2012-04-26 | Abbvie Inc. | Dual variable domain immunoglobin and uses thereof |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| DE602005018477D1 (de) | 2005-08-26 | 2010-02-04 | Pls Design Gmbh | Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| ATE525374T1 (de) | 2005-12-13 | 2011-10-15 | Incyte Corp | Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren |
| US20090215084A1 (en) | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| US20110212086A1 (en) | 2006-01-19 | 2011-09-01 | Genzyme Corporation | GITR Antibodies For The Treatment of Cancer |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| JP2009526857A (ja) | 2006-02-15 | 2009-07-23 | イムクローン・リミテッド・ライアビリティ・カンパニー | 機能性抗体 |
| SG170750A1 (en) | 2006-03-17 | 2011-05-30 | Biogen Idec Inc | Stabilized polypeptide compositions |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| US8946391B2 (en) | 2006-03-24 | 2015-02-03 | The Regents Of The University Of California | Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition |
| JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| EP2027153B1 (en) | 2006-05-25 | 2014-04-30 | Bayer Intellectual Property GmbH | Dimeric molecular complexes |
| US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| MX380352B (es) | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| PL2059535T3 (pl) | 2006-08-18 | 2014-04-30 | Novartis Ag | Przeciwciało specyficzne względem PRLR i jego zastosowanie |
| US8497246B2 (en) | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
| ATE531720T1 (de) | 2006-08-21 | 2011-11-15 | Genentech Inc | Aza-benzofuranylverbindungen und anwendungsverfahren dafür |
| PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
| AU2007342338A1 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies |
| BRPI0716680A2 (pt) | 2006-11-02 | 2013-09-24 | Daniel J Capon | "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo" |
| CA2668693A1 (en) | 2006-11-15 | 2008-05-22 | David E. Anderson | Therapeutic uses of tim-3 modulators |
| BRPI0719333A2 (pt) | 2006-11-22 | 2014-02-04 | Incyte Corp | Midazotriazinas e imidazopirimidinas como inbidores de cinase |
| CA2670696A1 (en) | 2006-11-27 | 2008-06-05 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| PT2091918E (pt) | 2006-12-08 | 2014-11-24 | Irm Llc | Compostos e composições como inibidores de proteína cinase |
| EP3012249A1 (en) | 2006-12-08 | 2016-04-27 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| EP2102241A2 (en) | 2006-12-15 | 2009-09-23 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| NZ594510A (en) | 2006-12-27 | 2012-06-29 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| DK2175884T3 (en) | 2007-07-12 | 2016-09-26 | Gitr Inc | Combination USING GITR BINDING MOLECULES |
| JP2010533649A (ja) | 2007-07-13 | 2010-10-28 | ザ ジョンズ ホプキンス ユニバーシティー | Ｂ７−ｄｃ改変体 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| CA2696263C (en) | 2007-08-15 | 2017-06-13 | Bing Liu | Monospecific and multispecific antibodies and method of use |
| US9243052B2 (en) | 2007-08-17 | 2016-01-26 | Daniel Olive | Method for treating and diagnosing hematologic malignancies |
| US20120039870A9 (en) | 2007-09-07 | 2012-02-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| CA2706200A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Immunoglobulin constructs comprising multiple single variable domains and an fc portion |
| EP2615115A3 (en) | 2007-11-30 | 2014-01-08 | Glaxo Group Limited | Antigen-binding constructs |
| PT2222675E (pt) | 2007-12-19 | 2013-11-13 | Genentech Inc | 5-anilinoimidazopiridinas e métodos de utilização |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| ES2796085T3 (es) | 2008-01-15 | 2020-11-25 | Univ Leland Stanford Junior | Marcadores de células madre de leucemia mieloide aguda |
| WO2009097394A2 (en) | 2008-01-29 | 2009-08-06 | The Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2252293B1 (en) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| JP2011515497A (ja) | 2008-03-26 | 2011-05-19 | セレラント セラピューティクス インコーポレイテッド | 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| EP2899209A1 (en) | 2008-04-29 | 2015-07-29 | Abbvie Inc. | Dual Variable Domain Immunoglobulins and uses thereof |
| BRPI0912882A2 (pt) | 2008-05-21 | 2017-05-16 | Incyte Corp | sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos |
| KR101257158B1 (ko) | 2008-05-23 | 2013-04-23 | 노파르티스 아게 | 단백질 티로신 키나제 억제제로서의 퀴놀린 및 퀴녹살린의 유도체 |
| BRPI0913406A2 (pt) | 2008-06-03 | 2018-01-09 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
| EP2297208A4 (en) | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| US20110177070A1 (en) | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
| JP5945096B2 (ja) | 2008-07-04 | 2016-07-05 | 小野薬品工業株式会社 | 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用 |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| BRPI0917791B1 (pt) | 2008-08-22 | 2022-03-22 | Novartis Ag | Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| BRPI0918268B1 (pt) | 2008-09-02 | 2021-08-03 | Novartis Ag | Derivados de picolinamida, seu uso, e composição farmacêutica |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| WO2010029434A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| US8586023B2 (en) | 2008-09-12 | 2013-11-19 | Mie University | Cell capable of expressing exogenous GITR ligand |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN102753193A (zh) | 2008-10-31 | 2012-10-24 | 比奥根艾迪克Ma公司 | Light靶向分子及其用途 |
| WO2010056735A1 (en) | 2008-11-11 | 2010-05-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity |
| SI2370593T1 (sl) | 2008-11-28 | 2016-08-31 | Emory University | Postopek za določanje učinkovitosti antagonista pd-1 |
| PL2370076T3 (pl) | 2008-11-28 | 2017-06-30 | Novartis Ag | Kombinacja farmaceutyczna zawierająca inhibitor Hsp 90 i inhibitor mTOR |
| WO2010065882A1 (en) | 2008-12-04 | 2010-06-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| WO2010084999A1 (en) | 2009-01-26 | 2010-07-29 | Protegene, Inc. | Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| TW201613969A (en) | 2009-03-05 | 2016-04-16 | Abbvie Inc | IL-17 binding proteins |
| WO2010102278A1 (en) | 2009-03-06 | 2010-09-10 | President And Fellows Of Harvard College | Methods and compositions for the generation and maintenance of regulatory t cells |
| US20120070450A1 (en) | 2009-03-24 | 2012-03-22 | Riken | Leukemia stem cell markers |
| JP5748653B2 (ja) | 2009-04-10 | 2015-07-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法 |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| ES2668874T3 (es) | 2009-04-30 | 2018-05-22 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anticuerpos anti-CEACAM1 y métodos de uso de los mismos |
| JP2012525155A (ja) | 2009-05-01 | 2012-10-22 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびこの使用 |
| MX2011011670A (es) | 2009-05-01 | 2011-11-18 | Abbott Lab | Inmunoglobulinas de dominio variable dual y usos de las mismas. |
| JP5808052B2 (ja) | 2009-05-29 | 2015-11-10 | 中外製薬株式会社 | Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物 |
| EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
| JP5456891B2 (ja) | 2009-06-26 | 2014-04-02 | ノバルティス アーゲー | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 |
| CN102822200A (zh) | 2009-07-20 | 2012-12-12 | 百时美施贵宝公司 | 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合 |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| RU2012112550A (ru) | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| SG178991A1 (en) | 2009-09-03 | 2012-04-27 | Schering Corp | Anti-gitr antibodies |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
| CN104826106B (zh) | 2009-09-30 | 2019-01-11 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
| US8716450B2 (en) | 2009-10-15 | 2014-05-06 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| PT2519543T (pt) | 2009-12-29 | 2016-10-07 | Emergent Product Dev Seattle | Proteínas de ligação de heterodímero e suas utilizações |
| WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
| CA2790134A1 (en) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Pd-1 modulation and uses thereof for modulating hiv replication |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2550517A1 (de) * | 2010-03-22 | 2013-01-30 | Leibniz-Institut für Plasmaforschung und Technologie e.V. | Aktive thermosonde |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| WO2011131472A1 (en) | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| US8841417B2 (en) | 2010-05-14 | 2014-09-23 | Abbvie Inc. | IL-1 binding proteins |
| CN103079644B (zh) * | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012018538A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Bioassays for determining pd-1 modulation |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| PE20140229A1 (es) | 2010-08-26 | 2014-03-27 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| JP2014500712A (ja) | 2010-11-02 | 2014-01-16 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| AR083705A1 (es) | 2010-11-04 | 2013-03-13 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2638066A4 (en) | 2010-11-09 | 2015-06-03 | Medimmune Llc | ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012088302A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
| US8814630B2 (en) | 2011-01-04 | 2014-08-26 | Carl T. Rittberger | PVC beehive |
| RU2013140685A (ru) | 2011-02-04 | 2015-03-10 | Дженентек, Инк. | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| AU2012236479B2 (en) | 2011-03-31 | 2016-10-20 | Merck Sharp & Dohme Llc | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| WO2012177788A1 (en) | 2011-06-20 | 2012-12-27 | La Jolla Institute For Allergy And Immunology | Modulators of 4-1bb and immune responses |
| US9132281B2 (en) | 2011-06-21 | 2015-09-15 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| MY193562A (en) | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| US9308253B2 (en) | 2011-09-19 | 2016-04-12 | The Johns Hopkins University | Cancer immunotherapy |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| DK2771364T3 (da) | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
| KR20140097245A (ko) | 2011-10-31 | 2014-08-06 | 머크 샤프 앤드 돔 코포레이션 | 개선된 특성을 갖는 항체의 제조 방법 |
| LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| GB201120527D0 (en) | 2011-11-29 | 2012-01-11 | Ucl Business Plc | Method |
| JP6385277B2 (ja) | 2011-12-01 | 2018-09-05 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 癌治療のための抗ｃｅａｃａｍ１組換え型抗体 |
| CN102492038B (zh) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | 抗人Tim-3的中和性单克隆抗体L3D及其用途 |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| ES2670667T3 (es) | 2012-05-15 | 2018-05-31 | Novartis Ag | Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1 |
| NZ701626A (en) | 2012-05-15 | 2016-02-26 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| MX357305B (es) | 2012-05-15 | 2018-07-04 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1. |
| AU2013261130A1 (en) | 2012-05-15 | 2014-10-23 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| KR102129636B1 (ko) | 2012-05-31 | 2020-07-03 | 제넨테크, 인크. | Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법 |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| MX2015001269A (es) | 2012-07-27 | 2015-05-08 | Novartis Ag | Prediccion de la respuesta al tratamiento con un inhibidor de jak/stat. |
| AU2013296919A1 (en) | 2012-07-30 | 2015-01-22 | Alex Wah Hin Yeung | Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator |
| WO2014022332A1 (en) | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| ES2848052T3 (es) | 2012-08-03 | 2021-08-05 | Dana Farber Cancer Inst Inc | Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso |
| TWI472974B (zh) | 2012-09-06 | 2015-02-11 | Au Optronics Corp | 多類物體觸控點偵測方法 |
| WO2014047350A1 (en) | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| US20150290316A1 (en) | 2012-10-02 | 2015-10-15 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| CA3201072A1 (en) | 2012-10-12 | 2014-04-17 | The Brigham And Women's Hospital, Inc. | Enhancement of the immune response |
| CA2890663A1 (en) | 2012-11-08 | 2014-05-15 | Novartis Ag | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| HK1211475A1 (en) | 2012-11-28 | 2016-05-27 | Novartis Ag | Combination therapy |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014165082A2 (en) | 2013-03-13 | 2014-10-09 | Medimmune, Llc | Antibodies and methods of detection |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP2981821B2 (en) | 2013-04-02 | 2021-11-03 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| SG11201508528TA (en) | 2013-05-02 | 2015-11-27 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| CN103242448B (zh) | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| WO2014195852A1 (en) | 2013-06-03 | 2014-12-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| SG11201600310QA (en) | 2013-07-16 | 2016-02-26 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| JP6586087B2 (ja) | 2013-08-20 | 2019-10-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| US10077305B2 (en) | 2013-09-10 | 2018-09-18 | Medimmune Limited | Antibodies against PD-1 and uses thereof |
| BR112016005303A2 (pt) | 2013-09-11 | 2017-09-12 | Medimmune Ltd | anticorpos anti-b7-h1 para tratamento de tumores |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| PT3702373T (pt) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
| KR20160055269A (ko) | 2013-09-20 | 2016-05-17 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물 |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| PT3049441T (pt) | 2013-09-27 | 2020-01-21 | Hoffmann La Roche | Formulações de anticorpos anti-pdl1 |
| CA2926856A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| RU2016122957A (ru) | 2013-11-11 | 2017-12-19 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
| WO2015081158A1 (en) | 2013-11-26 | 2015-06-04 | Bristol-Myers Squibb Company | Method of treating hiv by disrupting pd-1/pd-l1 signaling |
| WO2015088847A1 (en) | 2013-12-11 | 2015-06-18 | Glaxosmithkline Llc | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| BR112016013963A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| EP3092004A4 (en) | 2014-01-06 | 2017-02-22 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| CN113637692A (zh) | 2014-01-15 | 2021-11-12 | 卡德门企业有限公司 | 免疫调节剂 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| KR20160108568A (ko) | 2014-02-04 | 2016-09-19 | 인사이트 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합 |
| US11213583B2 (en) | 2014-02-05 | 2022-01-04 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| SG10202108879SA (en) | 2014-02-10 | 2021-09-29 | Merck Patent Gmbh | TARGETED TGFβ INHIBITION |
| CA2936962C (en) | 2014-03-14 | 2024-03-05 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| EP3149042B1 (en) | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
| WO2015195163A1 (en) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
| JP6526189B2 (ja) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用 |
| ES2791248T3 (es) * | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| CA2964367C (en) | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| US20170320954A1 (en) | 2014-11-17 | 2017-11-09 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| DK3277321T3 (da) | 2015-04-01 | 2024-09-02 | Anaptysbio Inc | Antistoffer, der er rettet mod T-celle-immunglobulin og mucin-protein 3 (TIM-3) |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| US20180207273A1 (en) * | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| CA2991857A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Novel combination for use in the treatment of cancer |
| US20180177872A1 (en) | 2015-07-29 | 2018-06-28 | Yong Jia | Combination of PD-1 antagonist with an EGFR inhibitor |
| PL3334431T3 (pl) | 2015-08-11 | 2020-03-31 | Novartis Ag | 5-bromo-2,6-di-(1H-pirazol-1-ilo)pirymidyno-4-amina do zastosowania w leczeniu nowotworu złośliwego |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| BR112018010211A2 (pt) | 2015-12-07 | 2019-02-05 | Merck Patent Gmbh | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| AU2017257505B2 (en) | 2016-04-25 | 2020-05-14 | Medimmune, Llc | Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies |
| MX2019015738A (es) | 2017-06-27 | 2020-02-20 | Novartis Ag | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. |
| AU2018302283B2 (en) | 2017-07-20 | 2025-07-10 | Novartis Ag | Dosage regimens of anti-LAG-3 antibodies and uses thereof |
| WO2019018640A1 (en) | 2017-07-21 | 2019-01-24 | Novartis Ag | POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF |
| CA3081602A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
-
2014
- 2014-01-31 JO JOP/2020/0096A patent/JOP20200096A1/ar unknown
-
2015
- 2015-01-30 EP EP19161959.2A patent/EP3560959B1/en active Active
- 2015-01-30 UY UY0001035973A patent/UY35973A/es not_active Application Discontinuation
- 2015-01-30 CU CU2016000118A patent/CU24427B1/es unknown
- 2015-01-30 CN CN201580017736.2A patent/CN106132991B/zh active Active
- 2015-01-30 NZ NZ761188A patent/NZ761188A/en not_active IP Right Cessation
- 2015-01-30 US US14/610,837 patent/US9605070B2/en active Active
- 2015-01-30 TW TW104103319A patent/TWI686406B/zh active
- 2015-01-30 ES ES19161959T patent/ES2972425T3/es active Active
- 2015-01-30 SG SG11201605627TA patent/SG11201605627TA/en unknown
- 2015-01-30 DK DK15705163.2T patent/DK3099717T3/da active
- 2015-01-30 HU HUE15705163A patent/HUE045065T2/hu unknown
- 2015-01-30 HR HRP20191083TT patent/HRP20191083T1/hr unknown
- 2015-01-30 PT PT15705163T patent/PT3099717T/pt unknown
- 2015-01-30 TW TW109103123A patent/TWI769434B/zh active
- 2015-01-30 CA CA2936863A patent/CA2936863A1/en active Pending
- 2015-01-30 SI SI201530788T patent/SI3099717T1/sl unknown
- 2015-01-30 LT LTEP15705163.2T patent/LT3099717T/lt unknown
- 2015-01-30 PL PL15705163T patent/PL3099717T3/pl unknown
- 2015-01-30 EA EA201691556A patent/EA201691556A1/ru unknown
- 2015-01-30 CR CR20160347A patent/CR20160347A/es unknown
- 2015-01-30 CN CN202110653998.5A patent/CN113896791A/zh active Pending
- 2015-01-30 MY MYPI2016702542A patent/MY187296A/en unknown
- 2015-01-30 WO PCT/US2015/013913 patent/WO2015117002A1/en not_active Ceased
- 2015-01-30 JP JP2016549254A patent/JP6539667B2/ja active Active
- 2015-01-30 EP EP15705163.2A patent/EP3099717B1/en active Active
- 2015-01-30 ME MEP-2019-177A patent/ME03489B/me unknown
- 2015-01-30 AU AU2015210750A patent/AU2015210750B2/en active Active
- 2015-01-30 MX MX2016009961A patent/MX375953B/es active IP Right Grant
- 2015-01-30 KR KR1020167023540A patent/KR102366218B1/ko active Active
- 2015-01-30 KR KR1020227005386A patent/KR20220028145A/ko not_active Ceased
- 2015-01-30 NZ NZ722042A patent/NZ722042A/en not_active IP Right Cessation
- 2015-01-30 PE PE2016001269A patent/PE20170330A1/es unknown
- 2015-01-30 EP EP23203095.7A patent/EP4324518A3/en not_active Withdrawn
- 2015-01-30 RS RS20190815A patent/RS59065B1/sr unknown
- 2015-01-30 PH PH1/2016/501482A patent/PH12016501482B1/en unknown
- 2015-01-30 ES ES15705163T patent/ES2732901T3/es active Active
- 2015-02-01 JO JOP/2015/0017A patent/JO3567B1/ar active
-
2016
- 2016-07-05 CL CL2016001716A patent/CL2016001716A1/es unknown
- 2016-07-10 IL IL246693A patent/IL246693B2/en unknown
- 2016-07-29 MX MX2020002694A patent/MX2020002694A/es unknown
- 2016-08-29 EC ECIEPI201670447A patent/ECSP16070447A/es unknown
-
2017
- 2017-02-14 US US15/432,819 patent/US10472419B2/en active Active
- 2017-03-17 US US15/462,585 patent/US9884913B2/en active Active
-
2019
- 2019-04-12 JP JP2019076078A patent/JP6856694B2/ja active Active
- 2019-06-27 CY CY20191100673T patent/CY1121893T1/el unknown
- 2019-09-30 US US16/588,063 patent/US11155620B2/en active Active
-
2020
- 2020-04-06 US US16/841,029 patent/US10981990B2/en active Active
- 2020-09-01 AU AU2020227017A patent/AU2020227017B2/en active Active
-
2021
- 2021-03-18 JP JP2021044910A patent/JP2021104025A/ja active Pending
- 2021-09-24 US US17/484,794 patent/US20220185883A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03489B (me) | Molekuli antitijela na tim-3 i njihove upotrebe | |
| IL304772A (en) | Antibodies, uses and methods | |
| IL259987A (en) | Antibody molecules to pd-1 and uses thereof | |
| IL262095A (en) | Anti-pacap antibodies and uses thereof | |
| HUE043363T2 (hu) | Antitest molekulák PD-1-hez és azok felhasználásai | |
| PT3116909T (pt) | Moléculas de anticorpos para lag-3 e suas utilizações | |
| EP3498840A4 (en) | ANTI-LAG-3 ANTIBODIES | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| HUE045307T2 (hu) | EGFRVIII-ellenes antitestek és alkalmazásaik | |
| PT3354729T (pt) | Anticorpo anti-garp | |
| HUE045216T2 (hu) | Anti-CD79B antitestek és alkalmazási eljárások | |
| HUE064791T2 (hu) | APRIL ellenes antitest molekulák és alkalmazásaik | |
| PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
| DK3149042T3 (da) | PD-L1-antistoffer og anvendelser deraf | |
| DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| LT3556777T (lt) | Daugiaspecifiniai antikūno konstruktai | |
| EP3238129C0 (en) | ENTRY VERIFICATION | |
| IL291164A (en) | Anti-nme antibody | |
| IL256099A (en) | Antibody | |
| PL3092003T3 (pl) | Nowe przeciwciało przeciw netrynie-1 | |
| GB201503812D0 (en) | Antibody molecules and uses thereof | |
| DK3110447T3 (da) | Anti-EGFR-antistof og anvendelser heraf | |
| HUE054148T2 (hu) | Anti-ORAI1 antitest | |
| EP3469003A4 (en) | ANTI-PRL3 ANTIBODIES |